Lectin Delivery

The effectiveness of ERTs in LSD treatment is dependent on the drug’s ability to reach lysosomes of all cell types contributing to disease pathologies. All current ERT products utilize high-mannose receptors or mannose-6-P receptors for cell uptake and lysosomal delivery. While successful in addressing most of the systemic symptoms, enzyme access to some tissue (e.g., brain, eye) is inadequate.  We are developing plant lectins as carriers to facilitate ERT access to a broader array of cell types and administration via transmucosal as well as i.v. routes.